Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Figure out How to Forestall Tooth Staining - 2Unfathomable and Entertaining Legal disputes That Surprise everyone
- 3Travels to Dream Objections in Europe
- 4As tetanus vaccination rates decline, doctors worry about rising case numbers
- 5How a niche Catholic approach to infertility treatment became a new talking point for MAHA conservatives
- Influencers are selling a delusional fantasy of being postpartum. Why is it so easy to believe?
- Moscow: Russia well-positioned to withstand oil market shocks
- 10 Fundamental Tips and Deceives to Lift Your Cell phone's Exhibition
- 'Supergirl' drops 1st teaser trailer: Watch Milly Alcock as Kara Zor-El and the return of Krypto the Superdog
- Flu cases are spiking earlier than usual. What you need to know.
- 'Here we go again': Businesses grapple with fuel costs
- Authorities Bust Camel Booze Smuggling Operation, Seize Nearly 2,000 Containers of Illegal Alcohol
- Posts falsely claim Netanyahu video fabricated to cover up his death
- Warnings rise for U.S. as severe flu strain causes outbreaks in Canada, U.K.
